TRI-611 Degrades ALK Fusion Proteins for Lung Cancer

Researchers have developed TRI-611, a selective and brain-penetrant molecular glue degrader that induces the degradation of ALK fusion proteins. This discovery, published online in Nature on September 9, 2026, presents a potentially new therapeutic strategy for treating ALK-positive non-small-cell lung cancer (NSCLC). The mechanism by which TRI-611 operates involves a previously undescribed recruitment motif for Cereblon (CRBN), a key component of the E3 ubiquitin ligase complex that targets proteins for degradation.

ALK fusion proteins are oncogenic drivers in a subset of NSCLC, meaning they are proteins that promote cancer cell growth and survival. Targeting these specific proteins has been a significant focus in cancer therapy. TRI-611's ability to selectively degrade these aberrant proteins offers a promising avenue for treatment. The compound's brain-penetrant nature is also noteworthy, suggesting potential applications in treating brain metastases, a common and challenging complication of NSCLC. The preclinical studies detailed in the Nature publication demonstrated TRI-611's anti-tumour activity, indicating its efficacy in reducing tumor growth in experimental models.

The development of molecular glue degraders represents a significant advancement in targeted protein degradation therapies. Unlike traditional drugs that inhibit protein function, molecular glues hijack the cell's natural protein disposal system to eliminate disease-causing proteins entirely. TRI-611's specific recruitment of CRBN through a novel motif suggests a refined approach to this technology, potentially leading to greater efficacy and fewer off-target effects. The research highlights the ongoing innovation in oncology drug discovery, moving towards more precise and effective treatments for complex diseases like NSCLC.

Non-small-cell lung cancer is the most common type of lung cancer, accounting for approximately 80-85% of all lung cancer diagnoses. ALK rearrangements are found in about 3-5% of NSCLC patients, making them a significant, albeit specific, patient population for targeted therapies. The development of drugs like TRI-611 that specifically target these genetic alterations offers hope for improved outcomes for these individuals. The preclinical success of TRI-611 warrants further investigation and clinical trials to assess its safety and efficacy in human patients, potentially ushering in a new era of treatment for ALK-positive NSCLC.